Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer

Authors

Andrea Apolo, National Institutes of Health, Bethesda, MD
Brian C. Baumann, Springfield Clinic, Springfield, IL
Hikmat Al-Ahmadie, Memorial Sloan Kettering Cancer Center, New York, NY
Leslie Ballas, Cedars Sinai Medical Center, Los Angeles, CA
Rick Bangs, Bladder Cancer Advocacy Network, Bethesda, MD
Kenneth Brothers, National Cancer Institute Bladder Cancer Task Force, Rockville, MD
Stephanie Cooper Greenberg, National Cancer Institute Bladder Cancer Task Force, Rockville, MD
Scott Delacroix, LSU Health Sciences Center - New OrleansFollow
James J. Dignam, University of Chicago, Chicago, IL
Jason A. Efstathiou, Harvard Medical School, Boston, MA
Adam S. Feldman, Harvard Medical School, Boston, MA
Jared C. Foster, National Cancer Institute, NIH, Bethesda, MD
Noah M. Hahn, Johns Hopkins University, Baltimore, MD
Emma Hall, The Institute of Cancer Research, London, UK
Donna E. Hansel, University of Texas MD Anderson Cancer Center, Houston, TX
Jean Hoffman-Censits, Johns Hopkins University, Baltimore, MD
Ashish M. Kamat, University of Texas MD Anderson Cancer Center, Houston, TX
Sophia C. Kamran, Harvard Medical School, Boston, MA
Francesca Khani, Weill Cornell Medicine, New York, NY
Seth P. Lerner, Baylor College of Medicine, Houston, TX
Robert Lipman, Bladder Cancer Advocacy Network, Bethesda, MD
Bhupinder Mann, NIH, Rockville, MD
David McConkey, Johns Hopkins University, Baltimore, MD
James McKiernan, Columbia University, New York, NY
Tracy L. Rose, University of North Carolina, Chapel Hill, NC
Angela B. Smith, University of North Carolina, Chapel Hill, NC
Catherine Tangen, Fred Hutchinson Cancer Research Center, Seattle, WA
Abdul Tawab Amiri, NIH, Bethesda, MD
Chana Weinstock, U. S. Food and Drug Administration, Silver Spring, MD
et al

Document Type

Article

Publication Date

2-24-2025

Publication Title

Bladder Cancer

Abstract

The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.

PubMed ID

40034245

Volume

11

Issue

1

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Apolo, Andrea; Baumann, Brian C.; Al-Ahmadie, Hikmat; Ballas, Leslie; Bangs, Rick; Brothers, Kenneth; Greenberg, Stephanie Cooper; Delacroix, Scott; Dignam, James J.; Efstathiou, Jason A.; Feldman, Adam S.; Foster, Jared C.; Hahn, Noah M.; Hall, Emma; Hansel, Donna E.; Hoffman-Censits, Jean; Kamat, Ashish M.; Kamran, Sophia C.; Khani, Francesca; Lerner, Seth P.; Lipman, Robert; Mann, Bhupinder; McConkey, David; McKiernan, James; Rose, Tracy L.; Smith, Angela B.; Tangen, Catherine; Amiri, Abdul Tawab; Weinstock, Chana; and al, et, "Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer" (2025). School of Medicine Faculty Publications. 3658.
https://digitalscholar.lsuhsc.edu/som_facpubs/3658
10.1177/23523735251319185